Malignant Group Research Articles

Clinical value of contrast-enhanced ultrasound combined with quantitative analysis in Bosniak ≥ II cystic renal masses.

The 2019 Bosniak classification has improved the precise and detailed quantitative evaluation criteria, making the diagnosis of cystic renal masses (CRMs) more accurate and objective. This study addresses the clinical value of quantitative analysis and aims to investigate the feasibility of combining contrast-enhanced ultrasound (CEUS) with quantitative analysis for diagnosing Bosniak ≥ II CRMs. We retrospectively obtained 58 CRMs with confirmed pathology, which underwent CEUS and Contrast-enhanced computer tomography (CECT) evaluations according to Bosniak classification between January 2013 and August 2024. These lesions were divided into benign and malignant groups, followed by a quantitative analysis of the morphological details detected by CEUS. All morphological parameters were compared, and the diagnostic efficiencies were evaluated using receiver operating characteristics (ROC) curves, logistic regression (LR) analysis, and diagnostic curve analysis (DCA). Additionally, a cohort of 72 lesions was monitored for a period of ≥ 3years, and changes in Bosniak classification were analyzed by categorizing them into stable, upgraded, and downgraded categories. The analysis revealed no statistically significant difference between CEUS and CECT in our cohort's malignancy predictive rates across different Bosniak grades (p = 0.640). All morphological quantitative parameters showed statistically significant differences between the two groups (p < 0.001). ROC curve analysis revealed that the sum of enhanced wall thickness and enhanced septum thickness among quantitative parameters had the highest AUC value (AUC: 0.9226). Both LR models demonstrated superior clinical diagnostic performance with similar level of accuracy between qualitative and quantitative analysis, as evidenced by ROC (AUC: 0.9470, 0.9619, respectively) and DCA analyses. None of the lesions in the follow-up cohort were upgraded, suggesting that CRMs are relatively stable tumors with a low malignant potential. This retrospective study demonstrated that CEUS combined with Bosniak classification and quantitative analysis could enhance diagnostic confidence in differentiating Bosniak ≥ II CRMs and could serve as a viable alternative to CECT in specific cases.

Effectiveness of systemic treatments for advanced non-clear cell renal cell carcinoma: a systematic review and meta-analysis

BackgroundNon-clear cell renal cell carcinoma (nccRCC) represents a heterogeneous group of malignancies with substantial differences in morphology, genetic profiles, clinical behavior, and prognosis. Optimal treatment for nccRCC remains unclear, largely extrapolated from evidence available for clear cell renal cell carcinoma (ccRCC). This study aimed to compare the efficacy of current mainstream drug treatments for nccRCC to provide clinical treatment guidance for advanced cases.MethodsWe systematically searched PubMed, Embase, and Cochrane databases for trials published up to January 2, 2024, including controlled and single-arm trials. Primary outcomes included overall response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).ResultsWe selected six randomized controlled trials (RCTs) comparing mammalian target of rapamycin inhibitors (mTORi) with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs). These trials included four first-line and two second-line studies, with a total of 398 advanced nccRCC patients. Pooled results showed that VEGFR-TKIs significantly improved PFS compared to mTORi in first-line treatment (relative risk [RR] = 1.387; 95% confidence interval [CI]: 1.04-1.85; p = 0.026). In a single-arm meta-analysis, we included 22 VEGFR-TKI trials, three mTORi trials, 12 immune checkpoint inhibitor (ICI) therapies, five chemotherapy trials, and 10 combination therapy trials. The pooled ORR ranged from 6% (95% CI: 0–16%) to 36% (95% CI: 27–44%), and the pooled DCR ranged from 54% (95% CI: 50–58%) to 81% (95% CI: 70–91%). Subgroup analysis of ICI showed a higher ORR in the PD-L1 positive group compared to the PD-L1 negative group (RR = 3.044; 95% CI: 1.623-5.709; p = 0.001).ConclusionThis systematic review and meta-analysis demonstrate that VEGFR-TKIs improve PFS in first-line treatment compared to mTORi. The single-arm meta-analysis suggest that combination therapies with different mechanisms result in better ORR and DCR. Furthermore, PD-L1 positive patients showed significantly better therapeutic responses with ICI treatment than PD-L1 negative patients.

Analysis of the application value of SUV in quantitative SPECT/CT for diagnosing benign and malignant bone lesions.

To analyze the application value of standardized uptake value (SUV) in quantitative single-photon emission computed tomography/computed tomography (SPECT/CT) based on the maximum expectation reconstruction algorithm for diagnosing benign and malignant bone lesions. A retrospective analysis was conducted on the clinical data of 83 patients suspected of bone metastasis who underwent quantitative SPECT/CT bone scans in our hospital from September 2023 to July 2024. A total of 91 high-metabolic bone lesions were outlined for SUV measurement, while the spinal SUV of patients with normal bone metabolism were outlined as the control group (46 vertebral bodies). The maximum SUV (SUVmax), mean SUV (SUVmean), and minimum SUV (SUVmin) of benign lesions (benign group), malignant lesions (malignant group), and the control group were measured and compared. Receiver operating characteristic (ROC) curves were plotted to analyze the diagnostic value of SUV in differentiating benign and malignant bone lesions using quantitative SPECT/CT. Based on the final diagnosis determined by pathology and/or imaging follow-up for 6-12 months or more, 50 malignant bone lesions and 41 benign bone lesions were identified. The levels of SUVmax, SUVmean, and SUVmin in the malignant and benign groups were higher than those in the control group, with the malignant group showing higher levels than the benign group (P<0.05). Receiver operating characteristic curve analysis showed that the areas under the curves for SUVmax, SUVmean, and SUVmin were 0.867, 0.909, and 0.896, respectively. The optimal cut-off value for SUVmax was 26.58g/mL, with a specificity of 100% and a sensitivity of 65.27%; for SUVmean, the optimal cutoff value was 12.75g/mL, with a sensitivity of 78.36% and a specificity of 93.54%; for SUVmin, the optimal cut-off value was 9.13g/mL, with a sensitivity and specificity of 81.42% and 89.87%, respectively. The diagnostic detection rate of quantitative SPECT/CT fusion imaging combined with SUVmean analysis (91.21%) was higher than that of conventional SPECT/CT fusion imaging qualitative analysis (74.73%) (P<0.05). Standardized uptake value in quantitative SPECT/CT to some extent supplements the qualitative analysis of tumor bone metastasis and benign bone lesions, offering a higher accuracy in diagnosing tumor bone metastasis and differentiating between benign and malignant lesions compared to conventional SPECT/CT bone fusion imaging.

Characteristics and prognosis of small bowel tumors: A retrospective study.

Small bowel tumors (SBTs) are a heterogeneous group of difficult-to-diagnose tumors that account for 2%-5% of all gastrointestinal tumors. Single-balloon enteroscopy greatly enhances the diagnosis and treatment of SBTs. However, few epidemiological studies have been conducted in Taiwan to determine the clinical profile of SBTs. To investigate the clinical characteristics, managements and prognosis of SBTs in a medical center in Taiwan. The study enrolled 51 patients aged 58.9 ± 8.8 years (range, 22-93) diagnosed with SBTs from November 2009 to July 2021. We retrospectively recorded clinical characteristics, indications, endoscopic findings, pathological results, management, and outcomes for further analysis. A male preponderance was observed (56.8%). The most common indications were suspected small intestinal tumors (52.9%) and obscure gastrointestinal bleeding (39.2%). The most common tumor location was the ileum (41.2%). The performance of imaging studies (P = 0.004) and the types of findings (P = 0.005) differed significantly between malignant and benign SBTs. The most frequent imaging finding was a small intestinal mass (43.1%). The top three malignant tumor types were gastrointestinal stromal tumors (GISTs), adenocarcinomas, and lymphomas. Moreover, the proportions of benign and malignant tumors were 27.5% and 72.5%, respectively. The survival rates of patients with malignant tumors in the GIST and non-GIST groups differed significantly (P = 0.015). Kaplan-Meier survival analysis showed a significant difference in survival between patients in the malignant and benign groups (P = 0.04). All patients with lymphoma underwent chemotherapy (n = 7/8, 87.5%), whereas most patients with GISTs underwent surgery (n = 13/14, 92.8%). Patients with GISTs have a significantly higher survival rate than those with other malignant SBTs. Therefore, a large-scale nationwide study is warranted to evaluate the population-based epidemiology of SBTs.

An observational study of clinico-pathological characteristics of gynecological tumors and mode of treatment

Background: Gynecological malignancies are a group of various malignancies of the female reproductive system which included cancers of the ovary, cervix, uterus, vulva, vagina, and also gestational trophoblastic neoplasia. Aims and Objectives: The aim of this study was to study the clinical profile, different histopathological types of gynecological tumors, and mode of treatment. Materials and Methods: Study was conducted on 94 patients from June 2022 to December 2022. Results: Mean age of study population was 49.54±14.54 years. On radiological examination, out of total 52 ovarian cancers, cysts were present in 14 (14.89%) women, solid cysts in 16 (17.02%), papillary projections in 9 (9.57%), vascularity in 11 (11.70%), and lymphadenopathy in 2 (2.12%) women. The Pipelle biopsy results showed complex hyperplasia with atypia in 6 women (6.38%), endometrial carcinoma in 2 women (2.12%), focal atypia in 3 women (3.19%), and simple hyperplasia with atypia in 7 women (7.44%). On Pap smear/liquid based cytology, 1 (1.06%) woman each had atypical squamous cells, HSIL cannot be excluded, atypical squamous cells of undetermined significance, high-grade squamous intraepithelial lesion, and low-grade squamous intraepithelial lesion. No intraepithelial lesion or malignancy was found in 82 (87.23%) women. Present study showed that cervix cases was 10 (10.63%), endometrium 30 (31.91%), and vaginal 1 (1.06%). Majority of women in the present study, that is, 53 (56.38%) had ovarian tumors. In endometrial cancer, endometrioid adenocarcinoma, that is, 15 (50%) followed by simple endometrial hyperplasia without atypia and complex endometrial hyperplasia with atypia, that is, 4 (13.33%) each. Conclusion: Maximum number of patients having various gynecological tumors presented with stage II disease and above but maximum women with ovarian cancer reported with stage III and stage IV. These results clearly explained that ovarian cancer usually had non-specific or misleading symptoms as compared to cervical cancer which reported few specific symptoms.

The value of contrast-enhanced energy-spectrum mammography combined with clinical indicators in detecting breast cancer in Breast Imaging Reporting and Data System (BI-RADS) 4 lesions.

Under the Breast Imaging Reporting and Data System (BI-RADS), category 4 lesions have a high probability of malignancy. This study sought to investigate the efficacy of a model that combined the BI-RADS score with the enhancement score and clinical indicators in the diagnosis of BI-RADS 4 lesions based on contrast-enhanced spectral mammography (CESM) in breast cancer patients. The data of female patients with BI-RADS scores of 4 who underwent CESM at the Department of Medical Imaging of the Third Affiliated Hospital of Soochow University from January 2018 to July 2023 were retrospectively collected. In total, 170 patients were enrolled in the study. Based on their surgery or puncture pathology results, the patients were divided into malignant and benign groups. The clinical data, imaging characteristics, and enhancement degree of the patients in the two groups were compared. Model 3, which combined the BI-RADS score, enhancement score, and clinical indicators, was constructed using logistic regression. The predictive performance of Model 3 was evaluated and compared with Model 1 (BI-RADS score) and Model 2 (BI-RADS score + enhancement score). Of the 170 patients, 69 had benign lesions and 101 had malignant lesions. There were significant differences between the malignant and benign groups in terms of age, menopause, a family history breast cancer, BI-RADS score, and enhancement score (all P<0.05). The areas under the curve (AUCs) of the receiver operator characteristic curves of Models 1, 2, and 3 were 0.830, 0.858, and 0.900, respectively. The best cut-off value for Model 3 was 0.766, with a sensitivity of 74.3% and a specificity of 94.2%. Based on the AUCs and decision curves, Model 3 performed better than Models 1 and 2. The calibration curve (intercept: 0.034; slope: 0.807) was plotted using bootstrap re-sampling (500 times), and showed good agreement between the predicted probability and the actual prevalence. In the suspected breast cancer patients with a BI-RADS score of 4, the combination of the enhancement score and clinical indicators based on the BI-RADS score improved the efficiency of CESM in diagnosing breast cancer.

A microfluidic chip incorporating magnetic sorting and invasive separation for isolation, culture and telomerase analysis of circulating tumor cells

Circulating tumor cells (CTCs) are a crucial indicator of cancer metastasis, and are vital for early diagnosis, disease monitoring, and treatment response evaluation. However, their extremely low concentration and the complexities of isolation techniques pose a significant challenge in capturing and analyzing CTCs. In this study, we developed a novel microfluidic system that integrates magnetic capture and invasive screening onto a single microfluidic chip. By attaching positively charged magnetic nanoparticles to negatively charged CTCs, the magnetic separation of CTCs within the chip effectively eliminates interference from blood cells. A total of 2 mL blood sample can be processed within 3 min, achieving an impressive tumor capture efficiency of 84%. Using the chip, we also successfully achieved long-term culture of CTCs, and identified CTCs with high activity and invasive potential in blood samples from 11 patients with colorectal cancer. Finally, we analyzed telomerase activity in cultured CTCs on the microfluidic chip. Significantly higher invasive potential and telomerase activity were observed in CTCs from the malignant tumor group compared to the benign group (P < 0.01), highlighting their increased aggressiveness. This study offers a novel approach for efficient CTCs isolation, culture, and telomerase analysis, clarifying the crucial role of telomerase in tumor metastasis and providing profound insights for future research on telomerase-targeted tumor metastasis.

Usage of Magnetic Resonance Imaging-Based Texture Analysis Features in Discrimination of Benign and Malignant Sinonasal Tumors

Aim: The objective of this study was to differentiate between benign and malignant sinonasal tumors using magnetic resonance imaging (MRI)-based texture analysis features. Materials and Method: Histopathologically proven benign or malignant sinonasal tumor patients were included in the study from MRI examinations performed between January 2013 and December 2020. Inclusion criteria included a tumor size of at least 1 cm and preoperative magnetic resonance imaging with axial T1W, axial fat-suppressed T2W, and axial T1W postcontrast sequences. After the images were transferred to a dedicated workstation, texture analysis calculations were performed. Differences between benign and malignant groups were compared. Results: The mean age of 37 patients (8 female, 29 male) included in the study was 50.8 ± 21.9 years. In our study, we found no statistically significant difference between malignant and benign sinonasal tumors in nine tissue analysis parameters obtained by MRI. Conclusion: MRI-based texture analysis needs identical MRI protocols for evaluating tumors. MRI-based texture analysis is not a useful diagnostic tool to discriminate between benign and malignant sinonasal tumors when specific pathologic types are not selected and scanning protocols are not identical.

Prognosticators of Optic Nerve Imaging in Malignant Pseudotumor Cerebri Syndrome.

Pseudotumor cerebri (PTC) syndrome is a disorder of increased intracranial pressure, most commonly affecting overweight women of childbearing age. Malignant PTC (MPTC) is a rare presentation that involves rapidly worsening vision, often necessitating surgical intervention to prevent permanent vision loss. The goal of this study was to determine whether radiographic findings of PTC are predictive of MPTC and the final visual outcome. Charts of patients diagnosed with PTC based on the modified Dandy criteria were reviewed. Snellen best-corrected visual acuity (BCVA), automated perimetry mean deviation (APMD), and papilledema grade were documented from the initial and final follow-up examinations. The MRI images were read by 2 neuroradiologists blinded to the clinical diagnosis, and consensus findings were obtained. The patients were classified into malignant and nonmalignant PTC groups. Malignant was defined as BCVA ≤ 20/200 or APMD ≤ -7 dB, and acute onset of symptoms. The sensitivity and specificity of each MRI finding for detecting MPTC was determined. Generalized linear model with random effect and backward model selection was performed to identify which radiographic findings were predictive of final BCVA, APMD, and papilledema grade. Overall, 114 eyes (57 malignant/57 nonmalignant) were included. No MRI finding has both sensitivity and specificity for MPTC reaching 60%. The highest sensitivity (86%) was flattening of the posterior globes and unilateral or bilateral transverse sinus stenosis. The highest specificities were completely empty sella (86%), enhancement (84%), and diffusion restriction (81%) of the prelaminar optic nerves. The presence of vertical tortuosity of the optic nerves was predictive of better final BCVA (P = 0.003) and better final APMD (P = 0.011). While papilledema grade was higher in MPTC, no MRI finding was predictive of papilledema grade. No single MRI finding has both high sensitivity and specificity for diagnosing MPTC. Vertical tortuosity of the optic nerves may be predictive of better final BCVA and APMD.

Potential Use of Exosomal Non-Coding MicroRNAs in Leukemia Therapy: A Systematic Review.

Leukemia is a heterogeneous group of hematological malignancies. Despite the enormous progress that has been made in the field of hemato-oncology in recent years, there are still many problems related to, among others, disease recurrence and drug resistance, which is why the search for ideal biomarkers with high clinical utility continues. Research shows that exosomes play a critical role in the biology of leukemia and are associated with the drug resistance, metastasis, and immune status of leukemias. Exosomes with their cargo of non-coding RNAs act as a kind of intermediary in intercellular communication and, at the same time, have the ability to manipulate the cell microenvironment and influence the reaction, proliferative, angiogenic, and migratory properties of cells. Exosomal ncRNAs (in particular, circRNAs and microRNAs) appear to be promising cell-free biomarkers for diagnostic, prognostic, and treatment monitoring of leukemias. This review examines the expression of exosomal ncRNAs in leukemias and their potential regulatory role in leukemia therapy but also in conditions such as disease relapse, drug resistance, metastasis, and immune status. Given the key role of ncRNAs in regulating gene networks and intracellular pathways through their ability to interact with DNA, transcripts, and proteins and identifying their specific target genes, defining potential functions and therapeutic strategies will provide valuable information.

Role of IFN-γ, IL-33, and IL-35 concentrations in tuberculous pleural effusion in diagnosis and analysis of the effectiveness of combined tests

This study examines the diagnostic utility of the combined interleukin-33 (IL-33), interferon-γ (IFN-γ), and interleukin-35 (IL-35) test in tuberculous pleural effusion. Forty patients with pleural effusion of unknown etiology admitted to the hospital between December 2020 and December 2023 were selected as the study group. The patients were further categorized into tuberculous (TB) (n = 20) and malignant (n = 20) groups on the basis of their relevant data, while sera from 20 healthy medical checkups were used as control group. Thoracentesis was used to collect pleural fluid, and after its collection, enzyme-linked immunosorbent assay was utilized to detect the concentration content of IL-35, IL-33, and IFN-γ in pleural fluid of patients with different types of diseases. Data processing and analysis were executed through SPSS23.0 software to plot the receiver operating characteristic curve and compare the area of the area under the line of each index. Adenosine deaminase level was statistically higher in TB group patients (59.91 U/L) than in malignant group (14.31 U/L) (P &lt; .05). Pleural fluid lactate dehydrogenase levels did not differ significantly between the 2 groups (P &gt; .05). T-SPOT test had a higher positive rate in the TB group (85%) and a lower positive rate in the malignant group (45%). The TB group exhibited significantly higher levels of IFN-γ expression than the malignant group (P &lt; .05). The TB group had higher levels of IL-33 and IL-35 compared to the malignant group, with a statistically significant difference (P &lt; .05). The TB group had a greater level of IL-33 (81.05 ± 10.11 pg/mL) than the cytology-positive group (39.37 ± 9.63 pg/mL), while the difference was not statistically significant (P &gt; .05). The level of IL-35 (70.11 ± 10.37 pg/mL) in the TB group was lower than the level of IL-35 (72.13 ± 9.58 pg/mL) in the cytology-positive group. The specificity of the series of combined tests reached 95.81%, which was statistically superior to the single-factor test (P &lt; .05). In the TB group, IFN-γ and IL-33, IFN-γ and IL-35, and IL-33 and IL-35 showed positive correlation. Combined determination of the concentration levels of IL-35, IL-33, and IFN-γ is of value in the diagnosis of tuberculous pleurisy.

The Value of Necrotic Area Features in Contrast-Enhanced Ultrasound for Distinguishing Between Benign and Malignant Subpleural Pulmonary Lesions

ObjectiveTo analyze Necrotic Area Features of subpleural pulmonary lesions (SPLs) demonstrated by contrast-enhanced ultrasound (CEUS) and investigate their value in differentiating between malignant and benign SPLs. MethodsPatients with SPLs who underwent CEUS at our hospital from January to May 2021. The following patient information was recorded: (i) age, (ii) sex, (iii) lesion size, (iv) lesion location, (v) size of necrotic areas and (vi) necrotic area morphology, including sieve-like necrosis, necrotic area with septal enhancement, necrotic area with annular enhancement margins, and necrotic area with burr-like enhancement margins. These parameters were analyzed using univariate and multivariate logistic regression. Subgroup analyses based on lesion size were further conducted using the collected data. ResultsA total of 212 patients with 212 SPLs were enrolled, comprising 99 benign and 113 malignant cases. Significant differences were observed between malignant and benign groups in terms of age, sex, lesion size and necrotic area morphology (all, p < 0.05). ConclusionNecrotic area's features observed on CEUS were valuable for distinguishing between benign and malignant SPLs. Age, sex, lesion size and the presence of burr-like enhancement margins are identified as independent predictors of malignant lesions.

Comparison of clinical features of patients with or without severe gastrointestinal complications in aggressive gastrointestinal lymphomas.

Aggressive primary gastrointestinal non-Hodgkin lymphoma (PGINHL) is an uncommon and heterogeneous group of lymphoid malignancies, that differs from indolent lymphoma and has a high incidence of severe gastrointestinal complications (GICs). To investigate and compare the clinicopathological characteristics, treatments and outcomes in the GICs and No-GICs group with aggressive PGINHL. This retrospective analysis was performed on aggressive PGINHL patients between January 2013 and December 2021 at our hospital. The independent influence factors of GICs were obtained by univariate and multivariate Logistic regression analysis, the selected variables significantly related to GICs were selected as the final predictors to construct nomogram. Kaplan-Meier curves further analyzed the survival of patients in GICs and No-GICs groups. Survival analysis of GICs group was performed using Cox regression. We focused on 124 aggressive PGINHL cases, which had a relatively high incidence 48.4% (60/124 cases) of GICs, the most common histological type in GICs group was diffuse large B-cell lymphoma (DLBCL) (n = 49, 81.7%). In the GICs group, small intestine was the most common anatomic site of lesion (43.3%), followed by large intestine (31.7%), and then stomach and esophagus (25.0%). Multivariate Logistic regression analysis showed that the independent risk factors for GICs were the small intestine [odd ratio (OR) = 3.33; 95% confidence interval (CI): 1.47-9.41; P = 0.009), aggressive B-cell (OR = 0.09; 95%CI: 0.01-0.83; P = 0.033), maximum tumor diameter (OR = 1.25; 95%CI: 1.07-1.47; P = 0.005), invaded deep serous layer (OR = 3.38; 95%CI: 1.24-9.19; P = 0.017). We developed a nomogram to predict risk of GICs in aggressive PGINHL patients based on independent risk factors. The value of area under curve calculated by receiver operating characteristic curve was 0.815, and calibration curve and decision curve analysis further indicated that the prediction effect was superior. The majority of patients with GICs were given combination therapy (chemotherapy combined with surgery or radiation). Event-free survival and overall survival in GICs group were no worse than those in the No-GICs group. The complication rate of GICs in patients with aggressive PGINHL was relatively high, particularly in PGI-DLBCL. The independent risk factors for GICs were the small intestine, PGI-TNKL, bulky tumor, and depth of invasion. A combination treatment, involving surgery, improved survival in the GICs group.

Abstract 4135327: Long-term Bleeding Events after Percutaneous Coronary Intervention in Patients with Malignancy with and without Anticoagulant Therapy

Background: With the aging population, the prevalence of malignancies in patients undergoing percutaneous coronary intervention (PCI) is increasing. Active malignancy is increasingly recognized as a significant contributor to high bleeding risks. In cases where anticoagulant (AC) therapy is required, it becomes crucial to determine which is the optimal choice for cancer patients, direct oral anticoagulants (DOACs) or warfarin. The aim of this study was to investigate long-term bleeding events in patients with malignancy undergoing PCI. Methods: CLIDAS (Clinical Deep Data Accumulation System) is a multicenter database with 7 tertiary medical hospitals in Japan. This retrospective analysis using CLIDAS database included 6838 patients who underwent PCI during April 2014 and March 2020 and also who have completed 3-year follow-up were divided into two groups; No malignancy group (n=6155) and malignancy group (n=683). Malignancy was defined as patients with treatment history of malignancy. Furthermore, these patients were categorized into six groups based on the presence of malignancy and the type of AC therapy; 1) No malignancy without AC (n=5369), 2) No malignancy with DOAC (n=294), 3) No malignancy with warfarin (n=492), 4) Malignancy without AC (n=586), 5) Malignancy with DOAC (n=44), and 6) Malignancy with warfarin (n=53). The primary outcome was the incidence of bleeding events, defined according to the Global Use of Streptokinase and t-PA for Occluded Coronary Arteries classification of moderate and severe bleeding. Results: During the 3-year follow-up period, 260 (3.8%) patients experienced major bleeding events after PCI. Among these patients, 180 (3.4%) were in group 1, 9 (3.1%) in group 2, 33 (6.7%) in group 3, 27 (4.6%) in group 4, 2 (4.5%) in group 5, and 9 (17.0%) in group 6. Multivariate Cox regression analysis showed that patients in the malignancy group had a significantly higher rate of bleeding events (HR, 1.50; 95% CI, 1.03-2.18). Furthermore, only the malignancy with warfarin group showed a significantly higher rate of bleeding events compared to the no malignancy without AC group (HR, 4.03; 95% CI, 1.94-8.37). Conclusions: Patients with malignancies receiving warfarin were associated with a higher risk of bleeding events. DOACs may be a safer alternative to warfarin in reducing bleeding risk in this population.

Predicting malignancy in breast lesions: enhancing accuracy with fine-tuned convolutional neural network models

BackgroundThis study aims to explore the accuracy of Convolutional Neural Network (CNN) models in predicting malignancy in Dynamic Contrast-Enhanced Breast Magnetic Resonance Imaging (DCE-BMRI).MethodsA total of 273 benign lesions (benign group) and 274 malignant lesions (malignant group) were collected and randomly divided into a training set (246 benign and 245 malignant lesions) and a testing set (28 benign and 28 malignant lesions) in a 9:1 ratio. An additional 53 lesions from 53 patients were designated as the validation set. Five models—VGG16, VGG19, DenseNet201, ResNet50, and MobileNetV2—were evaluated. Model performance was assessed using accuracy (Ac) in the training and testing sets, and precision (Pr), recall (Rc), F1 score (F1), and area under the receiver operating characteristic curve (AUC) in the validation set.ResultsThe accuracy of VGG19 on the test set (0.96) is higher than that of VGG16 (0.91), DenseNet201 (0.91), ResNet50 (0.67), and MobileNetV2 (0.88). For the validation set, VGG19 achieved higher performance metrics (Pr 0.75, Rc 0.76, F1 0.73, AUC 0.76) compared to the other models, specifically VGG16 (Pr 0.73, Rc 0.75, F1 0.70, AUC 0.73), DenseNet201 (Pr 0.71, Rc 0.74, F1 0.69, AUC 0.71), ResNet50 (Pr 0.65, Rc 0.68, F1 0.60, AUC 0.65), and MobileNetV2 (Pr 0.73, Rc 0.75, F1 0.71, AUC 0.73). S4 model achieved higher performance metrics (Pr 0.89, Rc 0.88, F1 0.87, AUC 0.89) compared to the other four fine-tuned models, specifically S1 (Pr 0.75, Rc 0.76, F1 0.74, AUC 0.75), S2 (Pr 0.77, Rc 0.79, F1 0.75, AUC 0.77), S3 (Pr 0.76, Rc 0.76, F1 0.73, AUC 0.75), and S5 (Pr 0.77, Rc 0.79, F1 0.75, AUC 0.77). Additionally, S4 model showed the lowest loss value in the testing set. Notably, the AUC of S4 for BI-RADS 3 was 0.90 and for BI-RADS 4 was 0.86, both significantly higher than the 0.65 AUC for BI-RADS 5.ConclusionsThe S4 model we propose has demonstrated superior performance in predicting the likelihood of malignancy in DCE-BMRI, making it a promising candidate for clinical application in patients with breast diseases. However, further validation is essential, highlighting the need for additional data to confirm its efficacy.

The Role of Peripheral Blood Inflammation Indices in Patients with a Diagnosis of Endometrial Hyperplasia and Cancer

Purpose: Endometrial cancer (EC) is an important problem with its increasing incidence, especially in developed countries. There is no generally accepted screening program yet. The management of endometrial hyperplasia (EH), which is the most important risk factor, is complex because it is an invasive process. Methods: A retrospective study was conducted with a total of 72 patients. Patients between the ages of 35-65 with abnormal uterine bleeding, and increased endometrial thickness on transvaginal sonography were evaluated with pathology results. Sociodemographic characteristics of the patients and laboratory values at hospital admission were obtained from hospital records. White blood cells (WBC), neutrophils, lymphocytes, monocytes, eosinophils, basophils, and thrombocyte counts (x10⁹/L); plateletcrit (%), hemoglobin (Hb) (g/dL), and hematocrit (Htc) (%) values were recorded. Neutrophil lymphocyte ratio (NLR), monocyte lymphocyte ratio (MLR), and thrombocyte lymphocyte ratio (TLR) were obtained. Systemic immune-inflammation index (SII), systemic inflammation response index (SIRI) and pan-immune-inflammation value (PIV) were obtained. Results: Thirty-seven patients diagnosed with EH and 35 patients diagnosed with endometrial malignancy were included. The mean age of the EH was 45.5 years and the mean age of the malignant group was 50.5 years (p=0.027). The sociodemographic characteristics of the patients were found to be similar. There was no significant difference in complete blood count parameters between two groups. Mean values of NLR were 2.33 and 2.52 in EH and EC groups, respectively, p = 0.448. Mean values of MLR were 0.20 and 0.21, respectively, p = 0.498. Mean values of TLR were 0.16 and 0.15, respectively, p = 0.811. Mean values of SII were 720.1 and 812.4 (x10⁹/L), respectively, p = 0.456. Mean values of SIRI were 943.1 and 1095.6 (x10⁹/L), respectively, p = 0.257. Mean values of PIV were 312753.6 and 352975.1 (x10⁹/L), respectively, p = 0.514. Conclusion: Peripheral blood inflammation indices have recently been used in cancer diagnosis and follow-up. We did not find any statistically significant differences in the investigated parametrers between the EH and EC patient groups. Close follow-up is necessary in the presence of additional risk factors in women with EH.

Ultrasonography (USG) Evaluation among Patients with Biliary Obstruction in a Tertiary Care Center

Background: Biliary obstruction is a blockage in the bile ducts that prevents bile from flowing from the liver to the small intestine. Objectives: This study aimed to assess the efficacy of ultrasonography (USG) among patients with a blockage in the bile ducts as known as biliary obstruction. Methods: This was a prospective observational study conducted at the Department of Radiology and Imaging at Sir Salimulliah Medical College Hospital, Dhaka, Bangladesh. This study included patients with clinical suspicion of biliary obstruction who underwent USG. Characteristics of the obstruction were evaluated for both benign and malignant lesions through USG. The findings were then correlated with ERCP, histopathology, or surgery to calculate the diagnostic performance of the former two modalities. Results: Out of 145 patients, 63 were in the malignant group and 82 were in the benign group. The sensitivity, specificity, and accuracy of detecting the nature of obstruction by USG were 33%, 84%, and 48.9%, respectively. The overall diagnostic accuracy of USG in predicting the site of obstruction was 64.3%. Hydatid Cyst and the Main Pancreatic Duct Stricture were the most accurate findings of USG. Conclusions: USG should be the initial screening modality of choice for predicting the level and nature of obstruction in patients with a clinical suspicion of obstructive jaundice.

Single-cell sequencing applications in acute myeloid leukemia.

Acute myeloid leukemia (AML) is a heterogeneous group of malignancies with poor prognosis. AML result from the proliferation of immature myeloid cells blocked at a variable stage of differentiation. Beyond inter-patient heterogeneity, AMLs are characterized by genetic and phenotypic intra-patient heterogeneity. Despite major advances in deciphering AML biology with bulk sequencing studies, pivotal questions remain unanswered. Analyses at the single-cell level could thus transform our understanding of these neoplasms. We review recent progresses in single-cell sequencing technologies from cell processing to bioinformatic pipelines. We next discuss how single-cell applications have helped understand the genetic and functional intra-leukemic heterogeneity, emphasizing aspects related to leukemic stem cells, clonal evolution and measurable residual disease (MRD) monitoring. We finally delineate how single-cell technologies could be implemented in routine clinical practice to improve patient management.

088. Transarterial Chemoembolization for Head and Neck Cancer: Case Series

Background: Head and neck cancers represent a diverse group of malignancies arising from the complex anatomy of the oral cavity, pharynx, larynx, nasal cavity, paranasal sinuses, and salivary glands. While traditional treatments like surgery, radiation, and chemotherapy remain mainstays, transarterial chemoembolization (TACE) has emerged as a potential therapeutic option, particularly for advanced or recurrent cases. We present two cases of head and neck cancer that receive TACE. Case: First Case: A 46 years old woman, with big lump on her left cheek. The patient was diagnosed with Basal Cell Adenocarcinoma T3N0M0 at right submandibular region. He has history of Docetaxel and Carboplatin 6 cycles chemotherapy. Second Case: A 51 years old man, complain a lump on his right tongue. The patient was diagnosed with Squamous Cell Carcinoma Well Differentiated at left glossus region. But no history of chemotherapy. Conclusion: Two cases with head and neck cancer in our center has good clinical outcome after receiving chemotherapy through TACE procedure. TACE is offering a targeted approach to deliver chemotherapy and induce tumor necrosis. Although, TACE is commonly used for liver cancer, but it demonstrates promising potential in improving outcomes for head and neck cancer patients in the future.

Bone marrow stromal cells enhance differentiation of acute myeloid leukemia induced by pyrimidine synthesis inhibitors.

Acute myeloid leukemia (AML) is a heterogeneous group of hematological malignancies characterized by differentiation arrest, high relapse rates, and poor survival. The bone marrow (BM) microenvironment is recognized as a critical mediator of drug resistance and a primary site responsible for AML relapse. Our previous study reported that 5-aminoimidazole-4-carboxamide ribonucleoside (AICAr) induces AML cell differentiation by inhibiting pyrimidine synthesis and activating Checkpoint kinase 1. Although the protective effect of BM stroma on leukemia cells in response to cytotoxic drugs is well-documented, its effect on AML differentiation remains less explored. In this study, we investigated the impact of stromal cell lines and primary mesenchymal stromal cells (MSCs) on AML cell line differentiation triggered by AICAr and brequinar, a known dihydroorotate dehydrogenase (DHODH) inhibitor. Our findings indicate that the mouse MS-5 stromal cell line, known for its cytoprotective effects, does not inhibit AML cell differentiation induced by pyrimidine synthesis inhibitors. Interestingly, AICAr caused morphological changes and growth arrest in MS-5 stromal cells via an AMP-activated protein kinase (AMPK)-dependent pathway. Human stromal cell lines HS-5 and HS-27, as well as primary MSCs isolated from patient bone marrow, were superior in promoting AML differentiation compared with mouse cells in response to AICAr and brequinar, with the inhibitors not significantly affecting the stromal cells themselves. In conclusion, our study highlights the supportive role of human BM MSCs in enhancing the differentiation effects of pyrimidine synthesis inhibitors on AML cells, suggesting that AML treatment strategies focusing on differentiation rather than cell killing may be successful in clinical settings.NEW & NOTEWORTHY This study is the first to demonstrate that human stromal cell lines and primary mesenchymal stromal cells from patients enhance the in vitro differentiation of acute myeloid leukemia (AML) cells induced by pyrimidine synthesis inhibitors, 5-aminoimidazole-4-carboxamide ribonucleoside (AICAr), and brequinar. Furthermore, this is the first report to show that AICAr affects mouse bone marrow stromal cells by activating AMP-activated protein kinase (AMPK) and that human stromal cells are superior to mouse cells for testing the effects of drugs on AML differentiation.